Literature DB >> 19995217

Postexposure rabies prophylaxis completed in 1 week: preliminary study.

Prapimporn Shantavasinkul1, Thanphet Tantawichien, Henry Wilde, Artikaya Sawangvaree, Apinya Kumchat, Natthasri Ruksaket, Vitool Lohsoonthorn, Pakamatz Khawplod, Terapong Tantawichien.   

Abstract

BACKGROUND: Patients exposed to a rabid animal often travel long distances to receive postexposure prophylaxis (PEP), which requires 4 or 5 visits. Reducing the number of clinic visits would not only reduce costs for the patient but may also help increase compliance to receive complete PEP. We made an effort to develop PEP completed in 1 week.
METHODS: We administered the 4-site intradermal injections of 0.1 mL of purified Vero cell rabies vaccine to the deltoids and thighs on days 0, 3, and 7, with and without equine rabies immunoglobulin (40 IU/kg). A control group received the World Health Organization-approved and widely used Thai Red Cross regimen (2-site intradermal injections on days 0, 3, and 7 and 1 injection on days 28 and 90) with equine rabies immunoglobulin. We then determined rabies neutralizing antibody (NAb) up to day 360.
RESULTS: Geometric mean titers for subjects receiving the 4-site intradermal regimen, with or without equine rabies immunoglobulin, had significantly higher NAb values than did the control group on day 14 and 28 (P<.001). All subjects in all groups had a NAb value > or =0.5 IU/mL on days 14 and 28. The percentages of subjects who had a NAb value > or =0.5 IU/mL from days 0 through 360 were not significantly different among the 3 groups.
CONCLUSIONS: After any PEP regimen, World Health Organization recommendations require a NAb value > or =0.5 IU/mL on days 14 and 28. The 1-week PEP regimen, therefore, appears promising. It increased immunogenicity over the 2-site intradermal schedule, and it is convenient and can be used in small clinics, because it consumes almost the entire supplied vaccine ampoule volume.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19995217     DOI: 10.1086/649211

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

1.  Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases.

Authors:  Ashwath Narayana; Aravind Manoharan; Madhusudana Shampur Narayan; Sudarshan Mysore Kalappa; Gangaboraiah Biligumba; Ravish Haradanahalli; Ashwini Manoor Anand
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Biting back: vaccine efforts redoubled as rabies deadline looms.

Authors:  Shraddha Chakradhar
Journal:  Nat Med       Date:  2015-01       Impact factor: 53.440

3.  Making rabies prophylaxis more economical: immunogenicity and safety results from a preliminary study using a 2-1 intramuscular regimen in healthy volunteers.

Authors:  Guihua Huang; Huazhang Liu; Qing Tang; Pengcheng Yu; Xinxin Shen; Yibin Zhang; Xiangyi Liu; Qing Cao; Chuanxi Fu; Beiyan Liu; Ming Wang
Journal:  Hum Vaccin Immunother       Date:  2013-09-05       Impact factor: 3.452

4.  Evaluation of a one week intradermal regimen for rabies post-exposure prophylaxis: results of a randomized, open label, active-controlled trial in healthy adult volunteers in India.

Authors:  Mysore Kalappa Sudarshan; Doddabele Hanumanthaiah Ashwath Narayana; Shampur Narayan Madhusudana; Ramesh Holla; Belludi Yajaman Ashwin; Bilagumba Gangaboraiah; Haradanahalli S Ravish
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

5.  Safety and Immunogenicity of a novel three-dose recombinant nanoparticle rabies G protein vaccine administered as simulated post exposure immunization: A randomized, comparator controlled, multicenter, phase III clinical study.

Authors:  Ravish H S; Akash Khobragade; Durga Satapathy; Monica Gupta; Surendra Kumar; Vinay Bhomia; Ramasubramanian V; Maharshi Desai; Ashok Dilipkumar Agrawal
Journal:  Hum Vaccin Immunother       Date:  2021-09-09       Impact factor: 4.526

6.  Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries.

Authors:  Katie Hampson; Sarah Cleaveland; Deborah Briggs
Journal:  PLoS Negl Trop Dis       Date:  2011-03-08

7.  Reemergence of rabies in Chhukha district, Bhutan, 2008.

Authors:  Basant Sharma; Navneet K Dhand; Nilkanta Timsina; Michael P Ward
Journal:  Emerg Infect Dis       Date:  2010-12       Impact factor: 6.883

8.  Shortening intradermal rabies post-exposure prophylaxis regimens to 1 week: Results from a phase III clinical trial in children, adolescents and adults.

Authors:  Phirangkul Kerdpanich; Pornthep Chanthavanich; Mari Rose De Los Reyes; Jodor Lim; Delia Yu; Ma Cecilia Ama; Zenaida Mojares; Daniela Casula; Ashwani Kumar Arora; Michele Pellegrini
Journal:  PLoS Negl Trop Dis       Date:  2018-06-06

9.  Persistence of Rabies Virus-Neutralizing Antibodies after Vaccination of Rural Population following Vampire Bat Rabies Outbreak in Brazil.

Authors:  Rita Medeiros; Viviane Jusot; Guy Houillon; Anvar Rasuli; Luzia Martorelli; Ana Paula Kataoka; Mohamed Ben Mechlia; Anne-Sophie Le Guern; Liliam Rodrigues; Rhomero Assef; Alvino Maestri; Reynaldo Lima; Yolande Rotivel; Valérie Bosch-Castells; Noël Tordo
Journal:  PLoS Negl Trop Dis       Date:  2016-09-21

10.  Human rabies in Côte d'Ivoire 2014-2016: Results following reinforcements to rabies surveillance.

Authors:  Issaka Tiembré; Anaïs Broban; Joseph Bénié; Mathilde Tetchi; Sophie Druelles; Maïna L'Azou
Journal:  PLoS Negl Trop Dis       Date:  2018-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.